Publications by authors named "R Bhambri"
Background: Numerous artificial intelligence (AI)-enabled tools for cardiovascular diseases have been published, with a high impact on public health. However, few have been adopted into, or have meaningfully affected, routine clinical care.
Objective: To evaluate current awareness, perceptions, and clinical use of AI-enabled digital health tools for patients with cardiovascular disease, and challenges to adoption.
Limited ground-based surveys and extensive remote sensing analyses have confirmed glacier thinning in the Garhwal Himalaya. More detailed studies on specific glaciers and the drivers of reported changes are essential to comprehend small-scale differences in the effects of climatic warming on Himalayan glaciers. We computed elevation changes and surface flow distribution for 205 (≥0.
View Article and Find Full Text PDFArticle Synopsis
- Tafamidis was approved for treating hereditary and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) in May 2019, based on the ATTR-ACT clinical trial findings.
- A retrospective study analyzed the prescription patterns of tafamidis among 430 patients with ATTRwt-CM from May 2019 to December 2020, finding that 100% were prescribed within 9 months of diagnosis.
- Key factors influencing the prescription included being age 65 or older, male, having heart failure/cardiomyopathy, and undergoing specific heart imaging tests, indicating a need for further studies on real-world outcomes for these patients.
Paddy rice fields (PRFs) are a potent source of global atmospheric greenhouse gases (GHGs), particularly CH and CO. Despite socio-environmental importance, the emission of GHGs has rarely been measured from Haryana agricultural fields. We have used new technology to track ambient concentration and soil flux of GHGs (CH, CO, and HO) near Karnal's Kuchpura agricultural fields, India.
View Article and Find Full Text PDFArticle Synopsis
- ATTR-CM is a serious heart condition typically seen in older adults, and the drug tafamidis is the first approved treatment since May 2019, shown to have high adherence rates in clinical trials.
- A study was conducted using Medicare claims data to examine how well patients adhered to their tafamidis prescriptions in the real world, along with their demographics and concurrent medications.
- Out of 3,558 patients evaluated, most were over 65, with significant percentages aged 75 to 84, indicating that the patient population reflects known demographics of those affected by ATTR-CM.